Posted On: 09/25/2016 9:38:07 AM
Post# of 99130
$GENE triple support $1.88
Nasdaq GM
9 bagger corrected
called 7/7/14 $1.16
Website
20-F 11/13/15
Headlines
and Filings
Genetic Technologies Limited operates as a molecular diagnostics company that offers predictive testing and assessment tools to help physicians in managing womens health. The companys lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. Genetic Technologies Limited markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons primarily in Australia and the United States. The company has partnerships with various suppliers, clinical researchers, and academic collaborators. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
Nasdaq GM
9 bagger corrected
called 7/7/14 $1.16
Website
20-F 11/13/15
Headlines
and Filings
Genetic Technologies Limited operates as a molecular diagnostics company that offers predictive testing and assessment tools to help physicians in managing womens health. The companys lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. Genetic Technologies Limited markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons primarily in Australia and the United States. The company has partnerships with various suppliers, clinical researchers, and academic collaborators. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
(0)
(0)
